Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments

PHILADELPHIA–(BUSINESS WIRE)–Fore Biotherapeutics, a precision oncology company focused on providing people with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines using its proprietary functional genomics platform, today announced the appointment of Kim Blackwell, M.D., as a member of the Board of Directors and R&D/Science Chair, and Sujit Basu, Ph.D., as Senior Vice President of Manufacturing and Technical Operations.

Dr. Blackwell is currently the Chief Medical Officer of Tempus Labs, a technology company applying artificial intelligence to advance precision medicine across life sciences. Prior to Tempus, she worked at Eli Lilly, where she was Vice President of Early Phase Oncology and Immuno-oncology. Before joining the drug development industry, Dr. Blackwell was a Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University, where she directed the Women’s Cancer Program, Strategic Collaborations, and the Precision Medicine Initiative for the Duke Cancer Institute. She also served as the principal or co-principal investigator for over 50 cancer clinical trials and co-founded the radiotherapeutics company Cereius. Dr. Blackwell was also included in TIME Magazine’s 100 Most Influential People in the World for 2013. She received her M.D. from Mayo Clinic Medical School, followed by training in internal medicine.

To the publication →